Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model

Hyeon Cheol Cho, Bo Hwan Kim, Kyunghoon Kim, Ju Youn Park, Jae Ho Chang, Soo Ki Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

While CpG oligodeoxynucleotides (ODN) are excellent candidates for cancer immunotherapeutics, the numbers of usable CpG ODNs are limited in current clinical settings. To resolve this, we investigated whether novel CpG ODN (KSK-CpG) would be an effective immunotherapeutic in a murine tumor model by affecting in vivo and in vitro parameters, such as survival span, the number of tumor nodules, natural killer (NK) cell and cytotoxic T lymphocyte (CTL) activity and interleukin (IL)-6 or IL-12 cytokine release in splenocytes. We found that KSK-CpG was effective in the murine cancer model by way of prolonging survival span, reducing the number of tumor nodules, augmenting NK cell and CTL cytotoxicity, as well as evoking IL-6 and IL-12 cytokine release in splenocytes. Collectively, these data demonstrate that KSK-CpG is active against the highly malignant B16BL6 and EL4 tumor mouse model via innate immune augmentation. Crown

Original languageEnglish
Pages (from-to)1401-1407
Number of pages7
JournalInternational Immunopharmacology
Volume8
Issue number10
DOIs
Publication statusPublished - 2008 Oct 1

Fingerprint

Oligodeoxyribonucleotides
Neoplasms
Cytotoxic T-Lymphocytes
Interleukin-12
Natural Killer Cells
Interleukin-6
Cytokines
Crowns

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Cho, Hyeon Cheol ; Kim, Bo Hwan ; Kim, Kyunghoon ; Park, Ju Youn ; Chang, Jae Ho ; Kim, Soo Ki. / Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model. In: International Immunopharmacology. 2008 ; Vol. 8, No. 10. pp. 1401-1407.
@article{574ef20faa51497cb306eef6c346fbb3,
title = "Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model",
abstract = "While CpG oligodeoxynucleotides (ODN) are excellent candidates for cancer immunotherapeutics, the numbers of usable CpG ODNs are limited in current clinical settings. To resolve this, we investigated whether novel CpG ODN (KSK-CpG) would be an effective immunotherapeutic in a murine tumor model by affecting in vivo and in vitro parameters, such as survival span, the number of tumor nodules, natural killer (NK) cell and cytotoxic T lymphocyte (CTL) activity and interleukin (IL)-6 or IL-12 cytokine release in splenocytes. We found that KSK-CpG was effective in the murine cancer model by way of prolonging survival span, reducing the number of tumor nodules, augmenting NK cell and CTL cytotoxicity, as well as evoking IL-6 and IL-12 cytokine release in splenocytes. Collectively, these data demonstrate that KSK-CpG is active against the highly malignant B16BL6 and EL4 tumor mouse model via innate immune augmentation. Crown",
author = "Cho, {Hyeon Cheol} and Kim, {Bo Hwan} and Kyunghoon Kim and Park, {Ju Youn} and Chang, {Jae Ho} and Kim, {Soo Ki}",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.intimp.2008.05.010",
language = "English",
volume = "8",
pages = "1401--1407",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "10",

}

Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model. / Cho, Hyeon Cheol; Kim, Bo Hwan; Kim, Kyunghoon; Park, Ju Youn; Chang, Jae Ho; Kim, Soo Ki.

In: International Immunopharmacology, Vol. 8, No. 10, 01.10.2008, p. 1401-1407.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cancer immunotherapeutic effects of novel CpG ODN in murine tumor model

AU - Cho, Hyeon Cheol

AU - Kim, Bo Hwan

AU - Kim, Kyunghoon

AU - Park, Ju Youn

AU - Chang, Jae Ho

AU - Kim, Soo Ki

PY - 2008/10/1

Y1 - 2008/10/1

N2 - While CpG oligodeoxynucleotides (ODN) are excellent candidates for cancer immunotherapeutics, the numbers of usable CpG ODNs are limited in current clinical settings. To resolve this, we investigated whether novel CpG ODN (KSK-CpG) would be an effective immunotherapeutic in a murine tumor model by affecting in vivo and in vitro parameters, such as survival span, the number of tumor nodules, natural killer (NK) cell and cytotoxic T lymphocyte (CTL) activity and interleukin (IL)-6 or IL-12 cytokine release in splenocytes. We found that KSK-CpG was effective in the murine cancer model by way of prolonging survival span, reducing the number of tumor nodules, augmenting NK cell and CTL cytotoxicity, as well as evoking IL-6 and IL-12 cytokine release in splenocytes. Collectively, these data demonstrate that KSK-CpG is active against the highly malignant B16BL6 and EL4 tumor mouse model via innate immune augmentation. Crown

AB - While CpG oligodeoxynucleotides (ODN) are excellent candidates for cancer immunotherapeutics, the numbers of usable CpG ODNs are limited in current clinical settings. To resolve this, we investigated whether novel CpG ODN (KSK-CpG) would be an effective immunotherapeutic in a murine tumor model by affecting in vivo and in vitro parameters, such as survival span, the number of tumor nodules, natural killer (NK) cell and cytotoxic T lymphocyte (CTL) activity and interleukin (IL)-6 or IL-12 cytokine release in splenocytes. We found that KSK-CpG was effective in the murine cancer model by way of prolonging survival span, reducing the number of tumor nodules, augmenting NK cell and CTL cytotoxicity, as well as evoking IL-6 and IL-12 cytokine release in splenocytes. Collectively, these data demonstrate that KSK-CpG is active against the highly malignant B16BL6 and EL4 tumor mouse model via innate immune augmentation. Crown

UR - http://www.scopus.com/inward/record.url?scp=50949102674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949102674&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2008.05.010

DO - 10.1016/j.intimp.2008.05.010

M3 - Article

C2 - 18687302

AN - SCOPUS:50949102674

VL - 8

SP - 1401

EP - 1407

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 10

ER -